Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction Patients in Convalescent Period.

• Status: Suspended
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sclnow Biotechnology Co., Ltd.
• Treatments: Aspirin; Atorvastatin; Atorvastatin Calcium; Calcium; Calcium, Dietary

Criteria

Inclusion Criteria:

• proved cerebral infarction by CT or MRI.

• no cerebrovascular disease before

• signed informed consent form

Exclusion Criteria:

• serious body and intracranial lesions (tumor, infection, etc.)

• patients repeated cerebral infarction attacks

• multi-foci of cerebral infarction

• history of drug dependence and mental disease

• disturbance of consciousness and non-compliance patients

• subjects who are HIV positive

• pregnant or lactation

• donor: HIV infected, Active hepatitis B/C infected, Syphilis antibody positive

• subjects/ donor: alcoholism, drug addicts or mental disease